Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of EA5 in Healthy Adults
NCT07256288Phase 1Completed
- Sponsor
- Lan-Yi Therapeutics
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of EA5 in paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and myasthenia gravis (MG) (6 arms), sponsored by Lan-Yi Therapeutics. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events. Started May 2023; status: completed.
02
Drugs
EA5
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)atypical hemolytic uremic syndrome (aHUS)myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT07256288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07256288.